Summit Therapeutics (LON:SUMM) announced its quarterly earnings data on Tuesday. The company reported GBX (8) (($0.11)) earnings per share for the quarter, beating analysts’ consensus estimates of GBX (10.60) (($0.14)) by GBX 2.60 ($0.03), Bloomberg Earnings reports. Summit Therapeutics had a negative net margin of 102.61% and a negative return on equity of 72.51%.
SUMM traded down GBX 2.50 ($0.03) on Thursday, reaching GBX 195 ($2.60). 5,768 shares of the company traded hands, compared to its average volume of 34,608. Summit Therapeutics has a one year low of GBX 140 ($1.86) and a one year high of GBX 269.70 ($3.59).
In related news, insider Prof Stephen Davies acquired 17,500 shares of the firm’s stock in a transaction that occurred on Monday, April 23rd. The stock was bought at an average price of GBX 126 ($1.68) per share, for a total transaction of £22,050 ($29,356.94).
Summit Therapeutics Company Profile
Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat genetic and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).
Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.